Bellicum Pharmaceuticals

173 articles with Bellicum Pharmaceuticals

• 

  Bellicum Weighs Options After Serious Safety Concerns Halt Only Trials

  3/15/2023

  Bellicum Pharmaceuticals has ended the only clinical trials evaluating its GoCAR-T cell product in combination with rimiducid following serious safety concerns. 

• Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

  3/14/2023

  Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients.

• Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

  2/16/2023

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually.

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 31, 2023

  1/31/2023

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options.

• Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

  1/19/2023

  Bellicum Pharmaceuticals, Inc. today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T ® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

• Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

  12/11/2022

  Bellicum Pharmaceuticals, Inc. announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center team at the 64th American Society of Hematology Annual Meeting and Exposition being held in New Orleans December 10-13, 2022.

• Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

  11/10/2022

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the third quarter 2022 and provided an operational update.

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 31, 2022

  10/31/2022

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options.

• Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa

  10/4/2022

  Bellicum Pharmaceuticals, Inc. today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally.

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022

  10/3/2022

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options.

• Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  9/1/2022

  Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid).

• Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update

  8/11/2022

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the second quarter 2022 and provided an operational update.

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022

  7/1/2022

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 2 new employees consisting of an aggregate of 135,000 stock options.

• Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update

  5/12/2022

  Bellicum Pharmaceuticals, Inc. reported financial results for the first quarter 2022 and provided an operational update.

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2022

  5/2/2022

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 3 new employees consisting of an aggregate of 33,000 stock options.

• Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

  3/24/2022

  Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2021 and provided an operational update.

• Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference

  1/26/2022

  Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference.

• 

  Clinical Catch-Up: December 6-10

  12/13/2021

  There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.

• Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

  12/13/2021

  Bellicum Pharmaceuticals, Inc. announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550, which requires stockholders’ equity of at least $2.5 million for continued listing of the company’s common stock.

• Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market

  12/6/2021

  Bellicum Pharmaceuticals, Inc. today announced positive interim data from its ongoing Phase 1/2 GoCAR-T clinical trials, including a confirmed partial response (PR) in the first cohort of mCRPC patients treated in the clinical trial for BPX-601.